Drugs最新文献_第8页

Arimoclomol: First Approval. 阿利莫洛尔：首次批准。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-12-24 DOI: 10.1007/s40265-024-02129-x

Susan J Keam

引用次数: 0

Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations. 晚期慢性髓性白血病：治疗困难的选择。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-12-06 DOI: 10.1007/s40265-024-02108-2

Ehab Atallah, Michael Deininger

{"title":"Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations.","authors":"Ehab Atallah, Michael Deininger","doi":"10.1007/s40265-024-02108-2","DOIUrl":"10.1007/s40265-024-02108-2","url":null,"abstract":"A small number of patients with chronic myeloid leukemia (CML) either present with or progress to the accelerated phase (AP) or blast phase (BP). This occurs in approximately 4-7% of patients with CML. Most patients who progress to BP-CML are of myeloid lineage, while approximately 30% are of lymphoid lineage. Due to the rarity of this condition, there are no large or randomized trials that can inform clinical decisions. Most data are from retrospective chart reviews or data from old studies when tyrosine kinase inhibitors (TKIs) were initially approved. In addition, the definition of these categories has been in continuous flux over the last 20 years, making applicability of data even more confusing. In some classifications, the cutoff is 30% blasts for the definition of BP-CML, while in others a cutoff of 20% is used. In addition, more recently the World Health Organization (WHO) classification omitted the accelerated phase and recognized only a two-phase disease, while the International Consensus Classification retained a three-phase definition and retained the accelerated phase. Therapy for patients with AP/BP-CML depends on several factors, including prior therapy, BCR::ABL1 mutation, co-morbidities, cell lineage, and eligibility for allogeneic stem cell transplantation (alloHCT). Patients with AP-CML at presentation have a relatively favorable prognosis and may not need alloHCT if they respond appropriately to therapy. For patients with AP-CML who progressed while on TKI therapy or those with BP-CML, alloHCT is considered the only curative therapy. Our goal is to review the available data on the therapy of patients with AP-CML and BP-CML.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"41-50"},"PeriodicalIF":13.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations. 用于治疗炎症性肠病的治疗性抗体的免疫原性：治疗和临床考虑因素。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-11-13 DOI: 10.1007/s40265-024-02115-3

Ole Haagen Nielsen, Alexander Hammerhøj, Mark Andrew Ainsworth, John Gubatan, Geert D'Haens

{"title":"Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.","authors":"Ole Haagen Nielsen, Alexander Hammerhøj, Mark Andrew Ainsworth, John Gubatan, Geert D'Haens","doi":"10.1007/s40265-024-02115-3","DOIUrl":"10.1007/s40265-024-02115-3","url":null,"abstract":"The introduction of tumor necrosis factor inhibitors has led to a paradigm shift in the management of inflammatory bowel disease (IBD). The subsequent introduction of both anti-integrins and cytokine blockers has since expanded the biologic armamentarium. However, immunogenicity, defined as the production of anti-drug antibodies (ADAs) to the prescribed biopharmaceutical, means a significant fraction of patients exposed to biologic agents will experience a secondary loss of response to one or more of the drugs. In clinical settings, immunogenicity may be caused by several factors, both patient related (e.g., underlying chronic disease, systemic immune burden, including previous biologic therapy failure, and [epi]genetic background) and treatment related (e.g., dose and administration regimens, drug physical structure, photostability, temperature, and agitation). Here, we outline these elements in detail to enhance biopharmaceutical delivery and therapy for patients with IBD. Moreover, concurrent immunomodulator medication may reduce the risks of ADA generation, especially when using the chimeric drug infliximab. Summarizing the latest developments and knowledge in the field, this review aims to provide strategies to prevent ADA production and information on managing non-responsiveness or loss of response to biologics. Better understanding of the molecular mechanisms underlying the formation of ADAs and the critical factors influencing the immunogenicity of biopharmaceuticals may lead to improved health outcomes in the IBD community that may benefit both the individual patient and society through lower healthcare expenses.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"67-85"},"PeriodicalIF":13.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Self-Administered Outpatient Parenteral Antimicrobial Therapy in the Treatment of Tuberculosis. 长期自我给药的门诊肠外抗菌药物治疗肺结核。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-12-29 DOI: 10.1007/s40265-024-02122-4

A Rauch, N Köhler, T T Brehm, N Zielinski, K Stoycheva, C Maier, L Böttcher, I Friesen, D Schaub, M Reimann, S Schmiedel, C Lange, B Kalsdorf

{"title":"Long-Term Self-Administered Outpatient Parenteral Antimicrobial Therapy in the Treatment of Tuberculosis.","authors":"A Rauch, N Köhler, T T Brehm, N Zielinski, K Stoycheva, C Maier, L Böttcher, I Friesen, D Schaub, M Reimann, S Schmiedel, C Lange, B Kalsdorf","doi":"10.1007/s40265-024-02122-4","DOIUrl":"10.1007/s40265-024-02122-4","url":null,"abstract":"Objectives: To investigate the safety profiles and clinical outcomes in a continuous cohort of tuberculosis (TB) patients from a clinical referral centre in Germany receiving self-administered outpatient parenteral antimicrobial therapy (sOPAT).Methods: We conducted a retrospective observational cohort study of patients receiving sOPAT after discharge from the Research Center Borstel in Germany between January 2015 and December 2020. Data were extracted from medical records.Results: In the observation period, 150 patients received parenteral antibiotics at the Research Center Borstel. Of these, 89 received sOPAT via a port catheter and were further analysed. The majority were male (n = 59, 66.3%), with a median age of 33.6 years (interquartile range-IQR 26.2-42.8). Most patients had multidrug-resistant (MDR)-TB (n = 56, 62.9%) or pre-extensively drug resistant (pre-XDR)-TB (n = 21; 23.6%). Fifty-eight (65.2%) patients received one and 24 patients (27.0%) received two parenteral drugs, most commonly capreomycin (n = 53, 59.6%) and meropenem (n = 44, 49.4%). The median duration of sOPAT was 7.4 months (IQR 5.2-17.2). In total, 71,128 intravenous drug administrations were recorded. One patient died of TB while another patient was lost to follow-up. Sixty-two (69.7%) patients completed the sOPAT regimen, the most common reason for premature discontinuation was adverse drug events (n = 12, 13.5%). There were eight (9.0%) port-related complications requiring port explantation (bloodstream infections: n = 6, local infection: n = 1, port thrombosis: n = 1).Conclusions: In selected patients requiring long-term intravenous anti-TB therapy, sOPAT is a feasible treatment option with a low risk of complications when adequate infrastructure and training are in place.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"87-96"},"PeriodicalIF":13.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142902626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xeligekimab: First Approval. Xeligekimab：首次批准。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-12-20 DOI: 10.1007/s40265-024-02125-1

Hannah A Blair

引用次数: 0

Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections. 耐碳青霉烯类鲍曼不动杆菌感染的治疗方法。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-11-28 DOI: 10.1007/s40265-024-02104-6

Alina Iovleva, Vance G Fowler, Yohei Doi

引用次数: 0

Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy. 中等强度他汀类药物加依折麦布：是时候重新考虑将其作为最佳初始降脂策略了。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-11-14 DOI: 10.1007/s40265-024-02113-5

Sha Li, Hui-Hui Liu, Jian-Jun Li

{"title":"Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy.","authors":"Sha Li, Hui-Hui Liu, Jian-Jun Li","doi":"10.1007/s40265-024-02113-5","DOIUrl":"10.1007/s40265-024-02113-5","url":null,"abstract":"Achievement of low-density lipoprotein cholesterol (LDL-C) targets is crucial for the prevention of cardiovascular disease (CVD) in individuals with dyslipidaemia who are at high risk. Current guidelines recommend high-intensity statins at the highest tolerated dose as initial treatment to achieve LDL-C goals. However, the real-world situation is dismal: high-intensity statins are underused and achievement of LDL-C goals is suboptimal. Various challenges exist in the implementation of the recommended initial treatment strategy, including hesitancy to use high-intensity statins, non-adherence, and side effects, and the response to high-intensity statins varies across individuals. Emerging studies have shown another line of lipid-lowering, moderate-intensity statins in combination with ezetimibe, presenting considerable efficacy/effectiveness, along with better safety and adherence compared to statin intensification alone. Here we review the clinical evidence, treatment guidelines and challenges associated with high-intensity statins, and summarise the evidence on the combination therapy, moderate-intensity statin plus ezetimibe, which is the core strategy recommended by the 2023 Chinese Guideline for Lipid Management, as a possible primary treatment to achieve the LDL-C targets across several populations. The upfront use of a moderate-intensity statin plus ezetimibe may improve LDL-C control and lead to the prevention of CVD in real-world settings.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"51-65"},"PeriodicalIF":13.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Xanomeline/Trospium Chloride: First Approval. Xanomeline/Trospium Chloride：首次批准。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-12-24 DOI: 10.1007/s40265-024-02126-0

Yahiya Y Syed

引用次数: 0

Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes. 麻疹管理的最新进展：流行病学、疫苗和治疗以及监管变化。

IF 13 1区医学

Drugs Pub Date : 2025-01-01 Epub Date: 2024-11-05 DOI: 10.1007/s40265-024-02117-1

Youssef Rizk, Giuseppe Lippi, Brandon M Henry, Kin Israel Notarte, John G Rizk

{"title":"Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes.","authors":"Youssef Rizk, Giuseppe Lippi, Brandon M Henry, Kin Israel Notarte, John G Rizk","doi":"10.1007/s40265-024-02117-1","DOIUrl":"10.1007/s40265-024-02117-1","url":null,"abstract":"Mpox, caused by the monkeypox virus (MPXV), is categorized into two primary clades: Clade I and Clade II, with notable outbreaks linked to Clade IIb. Historically endemic in Africa, recent years have seen significant global spread. The World Health Organization (WHO) declared mpox a Public Health Emergency of International Concern in August 2024, highlighting the emergence of Clade Ib outside Africa and the broadening demographic impact of the outbreak. This review updates the current status of mpox vaccines and treatments, including their safety and effectiveness. There are two US Food and Drug Administration (FDA)-approved vaccines for the prevention of mpox disease, JynneosTM and ACAM2000®. The JynneosTM vaccine, recommended for high-risk individuals, has seen limited uptake despite its efficacy in preventing disease. Tecovirimat, while FDA-approved for smallpox and available in the European Union for mpox, has shown mixed results in recent trials, with new data suggesting limited effectiveness in Clade I infections and emergence of new mutations with resistance to this drug. Brincidofovir and Vaccinia Immune Globulin Intravenous offer additional treatment options, particularly for severe cases, although their use is constrained by regulatory and logistical challenges. Furthermore, the WHO recently approved the first commercial molecular assay, the Alinity m MPXV assay by Abbott Molecular Inc., for emergency use-an essential step in expanding testing capacity in regions experiencing mpox outbreaks. These updates underscore the critical need for continued research to enhance therapeutic outcomes and adapt public health strategies. Ensuring equitable access to vaccines, treatments, and diagnostics remains a significant challenge as the global community responds to the evolving mpox situation.","PeriodicalId":11482,"journal":{"name":"Drugs","volume":" ","pages":"1-9"},"PeriodicalIF":13.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142575624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enlonstobart: First Approval. Enlonstobart：首次批准。

IF 13 1区医学

Drugs Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1007/s40265-024-02119-z

Matt Shirley

引用次数: 0